J&J Weighs Topamax Controlled-Release Formulation After Dropping Obesity Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Controlled-release topiramate was designed to avoid dosing and tolerability issues seen in obesity trials with immediate-release formulation. Phase II study in diabetes-related obesity shows no advantage for long-acting version, J&J says; the formulation remains under evaluation for other indications.